Kittles R A, Baffoe-Bonnie A B, Moses T Y, Robbins C M, Ahaghotu C, Huusko P, Pettaway C, Vijayakumar S, Bennett J, Hoke G, Mason T, Weinrich S, Trent J M, Collins F S, Mousses S, Bailey-Wilson J, Furbert-Harris P, Dunston G, Powell I J, Carpten J D
Department of Molecular Virology, Immunology and Medical Genetics, Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
J Med Genet. 2006 Jun;43(6):507-11. doi: 10.1136/jmg.2005.035790. Epub 2005 Sep 9.
The EphB2 gene was recently implicated as a prostate cancer (PC) tumour suppressor gene, with somatic inactivating mutations occurring in approximately 10% of sporadic tumours. We evaluated the contribution of EphB2 to inherited PC susceptibility in African Americans (AA) by screening the gene for germline polymorphisms.
Direct sequencing of the coding region of EphB2 was performed on 72 probands from the African American Hereditary Prostate Cancer Study (AAHPC). A case-control association analysis was then carried out using the AAHPC probands and an additional 183 cases of sporadic PC compared with 329 healthy AA male controls. In addition, we performed an ancestry adjusted association study where we adjusted for individual ancestry among all subjects, in order to rule out a spurious association due to population stratification.
Ten coding sequence variants were identified, including the K1019X (3055A-->T) nonsense mutation which was present in 15.3% of the AAHPC probands but only 1.7% of 231 European American (EA) control samples. We observed that the 3055A-->T mutation significantly increased risk for prostate cancer over twofold (Fisher's two sided test, p = 0.003). The T allele was significantly more common among AAHPC probands (15.3%) than among healthy AA male controls (5.2%) (odds ratio 3.31; 95% confidence interval 1.5 to 7.4; p = 0.008). The ancestry adjusted analyses confirmed the association.
Our data show that the K1019X mutation in the EphB2 gene differs in frequency between AA and EA, is associated with increased risk for PC in AA men with a positive family history, and may be an important genetic risk factor for prostate cancer in AA.
EphB2基因最近被认为是一种前列腺癌(PC)肿瘤抑制基因,约10%的散发性肿瘤中存在体细胞失活突变。我们通过筛查该基因的种系多态性,评估了EphB2对非裔美国人(AA)遗传性PC易感性的影响。
对来自非裔美国人遗传性前列腺癌研究(AAHPC)的72名先证者进行EphB2编码区的直接测序。然后使用AAHPC先证者以及另外183例散发性PC病例与329名健康AA男性对照进行病例对照关联分析。此外,我们进行了祖先调整关联研究,在所有受试者中调整个体祖先,以排除由于人群分层导致的虚假关联。
鉴定出10个编码序列变异,包括K1019X(3055A→T)无义突变,该突变在15.3%的AAHPC先证者中存在,但在231例欧裔美国人(EA)对照样本中仅为1.7%。我们观察到3055A→T突变使前列腺癌风险显著增加两倍多(Fisher双侧检验,p = 0.003)。T等位基因在AAHPC先证者中(15.3%)比在健康AA男性对照中(5.2%)明显更常见(优势比3.31;95%置信区间1.5至7.4;p = 0.008)。祖先调整分析证实了这种关联。
我们的数据表明,EphB2基因中的K1019X突变在AA和EA之间的频率不同,与有阳性家族史的AA男性患PC的风险增加相关,可能是AA前列腺癌的一个重要遗传风险因素。